ClinicalTrials.gg
TerminatedNCT03599622Updated Jul 3, 2024Results posted

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

A Phase 2 interventional study of BMS-986165 and Placebo in Granulomatous Colitis, Crohn's Disease and Crohn's Enteritis, sponsored by Bristol-Myers Squibb. Terminated at 259 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial terminated because of lack of efficacy in the short term acute phase

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.

Enrollment
8th of 16
239 · median 180
Started
2018
with 4 others
Phase 2
6 of 16
none open now
Registered
14th of 16
by date

Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 8th largest by enrollment, is one of 5 that started in 2018, is one of 6 in phase 2, and was the 14th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Crohn Disease by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.

03

Conditions studied

  • Granulomatous Colitis
  • Crohn's Disease
  • Crohn's Enteritis
  • Granulomatous Enteritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution
  • Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments
  • Must have active moderate to severe CD
  • Men and women must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Severe or fulminant colitis that is likely to require surgery or hospitalization
  • Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease
  • Previous exposure to BMS-986165 in any study
  • Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    BMS-986165 Dose 1

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 2

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percent of Participants Achieving Clinical Remission at Week 12

    Percent of participants achieving clinical remission at Week 12. Clinical remission is defined as achieving a Crohn's Disease Activity Index (CDAI) Score below 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

    Time frame: 12 weeks after first dose

  2. Percent of Participants Achieving Endoscopic Response at Week 12

    Endoscopic Response is defined as \>= 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for things like ulcers and inflammation. Each part is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

    Time frame: 12 weeks after first dose

Secondary outcomes

  1. Percent of Participants Achieving Clinical Response at Week 12

    Clinical response is defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of ≥ 100 points or a total CDAI score \< 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

    Time frame: 12 weeks after first dose

  2. Percent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 12

    The Patient Reported Outcomes 2 (PRO2) is a way for patients to report how they're feeling. It focuses on two things: how often they have loose or liquid stools, and how much abdominal pain they have. They keep track of these things every day for a week. Stool frequency is rated on a scale from 0 to 3, with 0 being the normal number of stools per day to 3 which is \>/=5 stools more than normal per day. The pain is rated on a scale from 0 to 3, with 0 being no pain and 3 being severe pain. The scores for these two things are added up to get a total score ranging from 0-6. If the average daily score for abdominal pain is 1 or less, and the average number of loose or liquid stools is 3 or less, then the disease might be in remission. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

    Time frame: 12 weeks after first dose

  3. Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12

    The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for ulcer size, ulcerated surface, inflamed surface, and stenosis. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants starting study treatment.

    Time frame: 12 weeks after first dose

07

Results

Posted Jul 3, 2024
Limitations and caveats
Trial terminated because of lack of efficacy in the short term acute phase.

Participant flow

This study has a treat-through design

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestonePlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Started6086849
Completed5984839
Not completed1210
Withdrew: Withdrawal by subject0100
Withdrew: Other reasons1110
Treatment Period
Participant flow — Treatment Period
MilestonePlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Started5984839
Completed1314144
Not completed4670695
Withdrew: Adverse event1120182
Withdrew: Lack of efficacy1812132
Withdrew: Withdrawal by subject511161
Withdrew: Other reasons4670
Withdrew: Lost to follow-up1000
Withdrew: Study terminated by sponsor720150
Withdrew: Site terminated by sponsor0100

Outcome measures

PrimaryPercent of Participants Achieving Clinical Remission at Week 12

Percent of participants achieving clinical remission at Week 12. Clinical remission is defined as achieving a Crohn's Disease Activity Index (CDAI) Score below 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

Time frame:
12 weeks after first dose
Reported as:
Number · Percent of Participants
Percent of Participants Achieving Clinical Remission at Week 12
Percent of ParticipantsPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Percent of Participants Achieving Clinical Remission at Week 1228.3 (16.9 to 39.7)32.6 (22.7 to 42.5)21.4 (12.7 to 30.2)22.2 (0.0 to 49.4)
Statistical analysis
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.5812 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): 4.3 · 95% CI -11.0 to 19.53 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.5812 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 1.2 · 95% CI 0.6 to 2.53 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.3720 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): -6.3 · 95% CI -20.2 to 7.66 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.3720 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 0.7 · 95% CI 0.3 to 1.56 mg BMS-986165 (numerator) vs Placebo (denominator)
PrimaryPercent of Participants Achieving Endoscopic Response at Week 12

Endoscopic Response is defined as \>= 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for things like ulcers and inflammation. Each part is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

Time frame:
12 weeks after first dose
Reported as:
Number · Percent of Participants
Percent of Participants Achieving Endoscopic Response at Week 12
Percent of ParticipantsPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Percent of Participants Achieving Endoscopic Response at Week 128.3 (1.3 to 15.3)23.3 (14.3 to 32.2)16.7 (8.7 to 24.6)33.3 (2.5 to 64.1)
Statistical analysis
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.0198 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): 15.0 · 95% CI 3.7 to 26.33 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.0198 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 3.4 · 95% CI 1.2 to 9.83 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.1584 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): 8.2 · 95% CI -2.6 to 19.06 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.1584 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 2.1 · 95% CI 0.7 to 6.16 mg BMS-986165 (numerator) vs Placebo (denominator)
SecondaryPercent of Participants Achieving Clinical Response at Week 12

Clinical response is defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of ≥ 100 points or a total CDAI score \< 150. CDAI is a tool that helps doctors measure how severe someone's Crohn's disease is. It uses questions about symptoms experienced over a week to calculate a score. The scores range from 0 to 600 and are classified into different categories. Scores from 0 to 149 suggest the disease may be in remission. Scores from 150 to 220 indicate mild activity. Scores from 220 to 450 mean the disease is moderate to severe. Scores from 451 to 600 indicate severe disease. Higher scores mean more severe symptoms. Baseline refers to the initial set of before data collected from participants before starting study treatment. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

Time frame:
12 weeks after first dose
Reported as:
Number · Percent of Participants
Percent of Participants Achieving Clinical Response at Week 12
Percent of ParticipantsPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Percent of Participants Achieving Clinical Response at Week 1240.0 (27.6 to 52.4)47.7 (37.1 to 58.2)38.1 (27.7 to 48.5)55.6 (23.1 to 88.0)
Statistical analysis
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.3464 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): 7.7 · 95% CI -8.2 to 23.63 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.3464 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 1.4 · 95% CI 0.7 to 2.83 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.8857 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): -1.2 · 95% CI -17.0 to 14.76 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.8857 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 1.0 · 95% CI 0.5 to 1.96 mg BMS-986165 (numerator) vs Placebo (denominator)
SecondaryPercent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 12

The Patient Reported Outcomes 2 (PRO2) is a way for patients to report how they're feeling. It focuses on two things: how often they have loose or liquid stools, and how much abdominal pain they have. They keep track of these things every day for a week. Stool frequency is rated on a scale from 0 to 3, with 0 being the normal number of stools per day to 3 which is \>/=5 stools more than normal per day. The pain is rated on a scale from 0 to 3, with 0 being no pain and 3 being severe pain. The scores for these two things are added up to get a total score ranging from 0-6. If the average daily score for abdominal pain is 1 or less, and the average number of loose or liquid stools is 3 or less, then the disease might be in remission. Risk Difference and Odds Ratio prespecified to be collected for 3 mg and 6 mg BMS-986165 arms only.

Time frame:
12 weeks after first dose
Reported as:
Number · Percent of Participants
Percent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 12
Percent of ParticipantsPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Percent of Participants Who Achieving Patient Reported Outcomes 2 (PRO2) Remission at Week 1225.0 (14.0 to 36.0)32.6 (22.7 to 42.5)20.2 (11.6 to 28.8)33.3 (2.5 to 64.1)
Statistical analysis
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.2841 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): 8.1 · 95% CI -6.7 to 22.93 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 3 mg BMS-986165 · Mantel Haenszel · p = 0.2841 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 1.5 · 95% CI 0.7 to 3.13 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.5417 (Based on a 2-sided test at a significance level of 0.025.) · Risk difference (rd): -4.2 · 95% CI -17.6 to 9.26 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo vs 6 mg BMS-986165 · Mantel Haenszel · p = 0.5417 (Based on a 2-sided test at a significance level of 0.025.) · Odds ratio (or): 0.8 · 95% CI 0.3 to 1.86 mg BMS-986165 (numerator) vs Placebo (denominator)
SecondaryChange From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12

The SES-CD score is a way to measure how severe a person's bowel disease is. It looks at five different parts of the bowel and checks for ulcer size, ulcerated surface, inflamed surface, and stenosis. Each is given a score from 0 to 3 based on how bad the disease is. These scores are then added together for a total score ranging from 0 to 60. Higher scores indicate more severe disease. Baseline refers to the initial set of before data collected from participants starting study treatment.

Time frame:
12 weeks after first dose
Reported as:
Mean · Change in Score on a Scale
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
Change in Score on a ScalePlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12-1.5 ± 4.3-2.5 ± 6.5-3.7 ± 5.5-5.6 ± 8.5
Statistical analysis
  • 3 mg BMS-986165 · ANCOVA · Mean difference (final values): -3.0 · 95% CI -4.3 to -1.8
  • Placebo vs 3 mg BMS-986165 · ANCOVA · p = 0.0428 (Based on a 2-sided test at a significance level of 0.025.) · Mean difference (final values): -1.9 · 95% CI -3.7 to -0.13 mg BMS-986165 (numerator) vs Placebo (denominator)
  • 6 mg BMS-986165 · ANCOVA · Mean difference (final values): -3.4 · 95% CI -4.8 to -2.0
  • Placebo vs 6 mg BMS-986165 · ANCOVA · p = 0.0177 (Based on a 2-sided test at a significance level of 0.025.) · Mean difference (final values): -2.3 · 95% CI -4.1 to -0.46 mg BMS-986165 (numerator) vs Placebo (denominator)
  • Placebo · Mean difference (final values): -1.2 · 95% CI -2.6 to 0.3
  • 12 mg BMS-986165 · ANCOVA · Mean difference (final values): -6.0 · 95% CI -9.7 to -2.3

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 63 months). SAEs and Other AEs were assessed from first dose to 30 days after last dose of study therapy (assessed for an average of 11 months up to approximately 24 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/60 (0%)6/59 (10.2%)33/59 (55.9%)
3 mg BMS-9861650/86 (0%)11/84 (13.1%)55/84 (65.5%)
6 mg BMS-9861650/84 (0%)5/83 (6%)55/83 (66.3%)
12 mg BMS-9861650/9 (0%)2/9 (22.2%)7/9 (77.8%)
6 mg BMS-986165 - Open Label0/161 (0%)15/161 (9.3%)86/161 (53.4%)
12 mg BMS-986165 - Open Label0/6 (0%)1/6 (16.7%)3/6 (50%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-9861656 mg BMS-986165 - Open Label12 mg BMS-986165 - Open Label
Breast abscessInfections and infestations0/590/840/830/90/1611/6
Infectious pleural effusionInfections and infestations0/590/840/830/90/1611/6
MediastinitisInfections and infestations0/590/840/830/90/1611/6
Crohn's diseaseGastrointestinal disorders3/595/842/831/96/1610/6
Hepatic cytolysisHepatobiliary disorders0/590/840/831/90/1610/6
SubileusGastrointestinal disorders1/590/840/830/90/1610/6
Abdominal abscessInfections and infestations1/590/840/830/90/1610/6
Anal abscessInfections and infestations1/590/840/830/90/1610/6
Lung abscessInfections and infestations1/590/840/830/90/1610/6
DepressionPsychiatric disorders1/590/840/830/90/1610/6
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlacebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-9861656 mg BMS-986165 - Open Label12 mg BMS-986165 - Open Label
Upper respiratory tract infectionInfections and infestations2/599/845/833/911/1611/6
Ventricular extrasystolesCardiac disorders1/590/840/830/90/1611/6
COVID-19Infections and infestations6/595/8411/830/922/1611/6
NasopharyngitisInfections and infestations3/596/845/830/912/1611/6
Rib fractureInjury, poisoning and procedural complications0/590/840/830/90/1611/6
Thoracic vertebral fractureInjury, poisoning and procedural complications0/590/840/830/90/1611/6
Traumatic haemothoraxInjury, poisoning and procedural complications0/590/840/830/90/1611/6
Breast haematomaReproductive system and breast disorders0/590/840/830/90/1611/6
CoughRespiratory, thoracic and mediastinal disorders1/593/843/830/91/1611/6
Crohn's diseaseGastrointestinal disorders9/5910/8410/831/917/1610/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165Total
Mean39.1 ± 16.739.5 ± 15.237.9 ± 14.637.4 ± 13.738.8 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165Total
Female223834397
Male3848506142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165Total
Hispanic or Latino272011
Not Hispanic or Latino5878809225
Unknown or Not Reported01203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo3 mg BMS-9861656 mg BMS-98616512 mg BMS-986165Total
Asian111312137
Black or African American11305
White4870688194
Other02002
Not Reported00101
08

Study locations

259 sites
  • Local Institution - 0258
    Los Angeles, California 90067-2015, United States
  • Local Institution - 0247
    Aurora, Colorado 80014, United States
  • Local Institution - 0001
    Hamden, Connecticut 06518, United States
  • Local Institution - 0255
    Clearwater, Florida 33756-3839, United States
  • Local Institution - 0259
    Jacksonville, Florida 32207-4958, United States
  • Local Institution - 0261
    Jacksonville, Florida 32224, United States
  • Local Institution - 0276
    Largo, Florida 33777, United States
  • Local Institution - 0232
    Miami, Florida 33136, United States
  • Local Institution - 0162
    New Port Richey, Florida 34653, United States
  • Local Institution - 0201
    Orlando, Florida 32808, United States
  • Local Institution - 0249
    Orlando, Florida 32832, United States
  • Local Institution - 0166
    Tampa, Florida 33606, United States
  • Local Institution - 0248
    Zephyrhills, Florida 33542, United States
  • Local Institution - 0277
    Suwanee, Georgia 30024, United States
  • Local Institution - 0358
    Suwanee, Georgia 30024, United States
  • Local Institution - 0319
    Chicago, Illinois 60637, United States
  • Local Institution - 0346
    Glenview, Illinois 60026, United States
  • Local Institution - 0301
    Indianapolis, Indiana 46202, United States
  • Local Institution - 0253
    Iowa City, Iowa 52242, United States
  • Local Institution - 0282
    Shreveport, Louisiana 71105, United States
  • Local Institution - 0003
    Chesterfield, Michigan 48047, United States
  • Local Institution - 0218
    Chesterfield, Michigan 48047, United States
  • Local Institution - 0047
    Wyoming, Michigan 49519, United States
  • Local Institution - 0223
    Ypsilanti, Michigan 48197, United States
  • Local Institution - 0231
    Jackson, Mississippi 39216, United States
  • Local Institution - 0156
    Ocean Springs, Mississippi 39564, United States
  • Local Institution - 0359
    Saint Louis, Missouri 63130, United States
  • Local Institution - 0011
    Las Vegas, Nevada 89123, United States
  • Local Institution - 0043
    Lake Success, New York 11042, United States
  • Local Institution - 0308
    New York, New York 10032, United States
  • Local Institution - 0226
    Monroe, North Carolina 28112, United States
  • Local Institution - 0349
    Oklahoma City, Oklahoma 73112, United States
  • Local Institution - 0238
    Hershey, Pennsylvania 17033, United States
  • Local Institution - 0125
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0122
    Sayre, Pennsylvania 18840, United States
  • Local Institution - 0357
    Wyomissing, Pennsylvania 19610, United States
  • Local Institution - 0105
    Charleston, South Carolina 29406, United States
  • Local Institution - 0072
    Nashville, Tennessee 37204, United States
  • Local Institution - 0264
    Arlington, Texas 76012, United States
  • Local Institution - 0246
    Garland, Texas 75044, United States
  • Local Institution - 0252
    San Antonio, Texas 78229, United States
  • Local Institution - 0307
    San Antonio, Texas 78229, United States
  • Local Institution - 0073
    Southlake, Texas 76092, United States
  • Local Institution - 0240
    Spring, Texas 77379, United States
  • Local Institution - 0302
    Tyler, Texas 75701, United States
  • Local Institution
    Lynchburg, Virginia 24502, United States
  • Local Institution - 0224
    Richmond, Virginia 23249, United States
  • Local Institution - 0327
    Seattle, Washington 98101, United States
  • Local Institution - 0266
    Seattle, Washington 98104, United States
  • Local Institution - 0191
    Seattle, Washington 98195, United States
  • Local Institution - 0331
    Vancouver, Washington 98664, United States
  • Local Institution - 0356
    Milwaukee, Wisconsin 53215-5217, United States
  • Local Institution - 0268
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0254
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0265
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0289
    Woodville, South Australia 5011, Australia
  • Local Institution - 0042
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0041
    Clayton, Victoria 3168, Australia
  • Local Institution - 0040
    Melbourne, Victoria 3065, Australia
  • Local Institution - 0351
    Melbourne, Victoria 3181, Australia
  • Local Institution - 0275
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0316
    Antwerpen, 2018, Belgium
  • Local Institution - 0305
    Edegem, 2650, Belgium
  • Local Institution - 0322
    Gent, 9000, Belgium
  • Local Institution - 0314
    Yvoir, 5530, Belgium
  • Local Institution - 0256
    Salvador, Bahia 40110-060, Brazil
  • Local Institution - 0262
    Salvador, Bahia 40150-150, Brazil
  • Local Institution - 0069
    Juiz de Fora, Minas Gerais 26033-318, Brazil
  • Local Institution - 0086
    Porto Alegre, Rio Grande Do Sul 90035-003, Brazil
  • Local Institution - 0058
    Botucato, Sao Paulo 18618-970, Brazil
  • Local Institution - 0059
    Santo Andre, Sao Paulo 09060-650, Brazil
  • Local Institution - 0045
    Sao Bernardo do Campo, SAO Paulo 09715-090, Brazil
  • Local Institution - 0085
    Sao Jose do Rio Preto, SAO Paulo 15090-000, Brazil
  • Local Institution - 0017
    Rio de Janeiro, 21941-913, Brazil
  • Local Institution - 0048
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution - 0324
    Edmonton, Alberta T5R 1W2, Canada
  • Local Institution - 0300
    Edmonton, Alberta T6K 4B2, Canada
  • Local Institution - 0159
    Vancouver, British Columbia V5Z1M9, Canada
  • Local Institution - 0283
    Etobicoke, Ontario M9V 4B8, Canada
  • Local Institution - 0312
    London, Ontario N6A 5A5, Canada
  • Local Institution - 0236
    Toronto, Ontario M4N 3M5, Canada
  • Local Institution - 0317
    Montreal, Quebec H3G 1A4, Canada
  • Local Institution - 0280
    XIamen, Fujian 361004, China
  • Local Institution - 0225
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0228
    Guangzhou, Guangdong 510655, China
  • Local Institution - 0221
    Changsha, Hunan 410011, China
  • Local Institution - 0220
    Nanjing, Jiangsu 210011, China
  • Local Institution - 0306
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0250
    Changchun Shi, Jilin 130033, China
  • Local Institution - 0299
    Shenyang, Liaoning 110022, China
  • Local Institution - 0219
    Shanghai, Shanghai 200025, China
  • Local Institution - 0234
    Shanghai, Shanghai 200120, China
  • Local Institution - 0337
    Brno, 602 00, Czechia
  • Local Institution - 0360
    Brno, 602 00, Czechia
  • Local Institution - 0057
    Hradec Kralove, 500 12, Czechia
  • Local Institution - 0352
    Ostrava, 702 00, Czechia
  • Local Institution - 0071
    Ostrava, 708 52, Czechia
  • Local Institution - 0350
    Pardubice, 532 03, Czechia
  • Local Institution - 0075
    Praha 9, 190 00, Czechia
  • Local Institution - 0192
    Aalborg, 9210, Denmark

Showing the first 100 of 259 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Dec 2022, 52 months.

Results were first posted in Jul 2024, 1 year 6 months after primary completion. A results delay was requested in Sep 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2018
First posted
Jul 26, 2018
StartActual
Jul 16, 2018
Primary completionActual
Dec 12, 2022
CompletionActual
Oct 23, 2023
Results delay requested
Sep 8, 2023
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03599622
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Jul 16, 2018
Primary completion
Dec 12, 2022
Completion
Oct 23, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion